国泰君安证券股份有限公司 关于卫宁健康科技集团股份有限公司 2023年半年度持续督导跟踪报告 | 保荐机构名称：国泰君安证券股份有限公司 | 被保荐公司简称：卫宁健康 | | --- | --- | | 保荐代表人姓名：王雪萍 | 联系电话：021-38032704 | | 保荐代表人姓名：樊愈波 | 联系电话：021-38677656 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是。及时审阅公司公开信息披露文件，包括： 公司定期报告，股东大会、董事会、监事会公 | | | 告文件及其他公告文件等 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2.督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 | | | 限于防止关联方占用公司资源的制度、募集资金 | 是 | | 管理制度、内控制度、内部审计制度、关联交易 | | | 制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （ ...

国泰君安证券股份有限公司关于卫宁健康科技集团股份有限公司 2023 年持续督导定期现场检查报告 保荐机构名称：国泰君安证券股份有限公司 被保荐机构简称：卫宁健康 保荐代表人姓名：王雪萍 联系电话：021-38032704 保荐代表人姓名：樊愈波 联系电话：021-38677656 现场检查人员姓名： 王雪萍、樊愈波、余见影 现场检查对应期间：2023 年度 现场检查时间：2023 年 8 月 7 日 一、现场检查事项 现场检查意见 是 否 不适用 （一）公司治理 现场检查手段： （1）查阅历次董事会、监事会、股东大会会议材料，包括会议通知、会议决 议、会议记录、签到表、公告等； （2）查阅公司章程及各项规章制度； （3）与公司董事会办公室及其他部门相关人员进行访谈，了解公司基本制度的 执行情况； （4）与公司相关部门人员进行访谈，了解公司与关联企业在人员、资产、财 务、机构、业务等方面是否存在影响独立性的情形。 1．公司章程和公司治理制度是否完备、合规 √ 2．公司章程和三会规则是否得到有效执行 √ 3．三会会议记录是否完整，时间、地点、出席人员及 会议内容等要件是否齐备，会议资料是否保存完整 √ 4．三会会 ...

证券代码：300253 证券简称：卫宁健康 公告编号：2023-072 卫宁健康科技集团股份有限公司 第五届监事会第三十次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）于 2023 年 8 月 16 日以现场表决方式召开第五届监事会第三十次会议。会议 通知于 2023 年 8 月 4 日以专人送达及电子邮件方式发出。会议应出 席监事 3 人，实际出席监事 3 人。本次监事会的召集和召开符合《中 华人民共和国公司法》和《公司章程》的规定。会议由监事会主席李 琳主持。经全体监事表决，形成决议如下： 一、会议以 3 票同意、0 票反对、0 票弃权的结果审议通过了《关 于 2021 年股权激励计划相关事项调整的议案》 鉴于实施 2021 年权益分派方案（每 10 股派发现金 0.2 元）、2022 年权益分派方案（每 10 股派发现金 0.1 元），拟将首次授予限制性股 票授予价格由 13.925 元/股调整为 13.895 元/股；鉴于实施 2022 年 权益分派方案（每 10 股派发现金 0.1 元） ...

证券代码：300253 证券简称：卫宁健康 公告编号：2023-071 卫宁健康科技集团股份有限公司 第五届董事会第三十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）于 2023 年 8 月 16 日在公司会议室以现场和通讯方式召开了第五届董事会第 三十一次会议。会议通知于 2023 年 8 月 4 日以专人送达或电子邮件 方式发出。会议应出席董事 7 人，实际出席董事 7 人。本次董事会的 召集和召开符合《中华人民共和国公司法》和《公司章程》的规定。 会议由董事长周炜主持，公司监事及高级管理人员列席了本次董事 会。经与会董事表决，形成决议如下： 一、会议以 5 票同意、0 票反对、0 票弃权的结果审议通过了《关 于 2021 年股权激励计划相关事项调整的议案》 鉴于实施 2021 年权益分派方案（每 10 股派发现金 0.2 元）、2022 年权益分派方案（每 10 股派发现金 0.1 元），拟将首次授予限制性 股票授予价格由 13.925 元/股调整为 13.895 元/股；鉴于实施 20 ...

上海市广发律师事务所 关于卫宁健康科技集团股份有限公司 2021 年股权激励计划相关事项的法律意见 致：卫宁健康科技集团股份有限公司 上海市广发律师事务所（以下简称"本所"）接受卫宁健康科技集团股份有 限公司（以下简称"公司"）的委托，作为其 2021 年限制性股票激励计划（以 下简称"2021 年股权激励计划"）的专项法律顾问，就本次 2021 年股权激励计 划相关事项，根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中 华人民共和国公司法》（以下简称"《公司法》"）、中国证券监督管理委员会 （以下简称"中国证监会"）颁布的《上市公司股权激励管理办法》（以下简称 "《管理办法》"）、《深圳证券交易所创业板股票上市规则（2023 年修订）》 （以下简称"《上市规则》"）、《深圳证券交易所创业板上市公司自律监管指 南第 1 号——业务办理（2023 年 2 月修订）》（以下简称"《创业板自律监管 指南第 1 号》"）等法律、法规、规范性文件以及《卫宁健康科技集团股份有限 公司章程》（以下简称"《公司章程》"）、《卫宁健康科技集团股份有限公司 2021 年限制性股票激励计划（草案）》（以下简称"《202 ...

卫宁健康科技集团股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 编制单位：卫宁健康科技集团股份有限公司 | | | | | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金 | | 占用方与 上市公司 | 上市公司核算的 | 2023 年初 | 2023 年度占 | 2023 年半 年度占用资 | 2023 年半 | 2023 年半 年度末占 | | | | 占用 | 资金占用方名称 | 的关联关 | 会计科目 | 占用资金余 | 用累计发生金 | 金的利息 | 年度偿还累 | 用资金余 | 占用形成原因 | 占用性质 | | | | | | 额 | 额(不含利息) | | 计发生金额 | | | | | | | 系 | | | | (如有) | | 额 | | | | 现大股东及其 | | 无 | | | | | | | | | | 附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | ...

证券代码：300253 证券简称：卫宁健康 公告编号：2023-070 债券代码：123104 债券简称：卫宁转债 卫宁健康科技集团股份有限公司 《上海证券报》、《证券时报》和巨潮资讯网（www.cninfo.com.cn）， 公司披露的信息均以在上述指定媒体刊登的信息为准。请广大投资者 理性投资，注意风险。 特此公告。 卫宁健康科技集团股份有限公司 董 事 会 二○二三年八月十四日 关于公司实际控制人、董事长正常履职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）于 2023 年 7 月 3 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于公司 实际控制人、董事长被留置的公告》（公告编号：2023-064），于 2023 年 7 月 5 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于 公司实际控制人、董事长被留置的进展公告》（公告编号：2023-066）， 公司实际控制人、董事长周炜先生因涉嫌行贿被茂名市监察委员会立 案调查及实施留置。 2023 年 8 月 14 日， ...

Sales and Revenue - The total sales amount from the top five customers is ¥165,412,462.81, accounting for 5.35% of the annual total sales[1]. - The company's revenue for 2022 was CNY 3,092,864,688.21, representing a 12.46% increase from CNY 2,750,202,059.34 in 2021[76]. - Quarterly revenue for Q4 2022 reached CNY 1,221,899,498.11, contributing to the overall annual growth[77]. - The revenue from healthcare information technology business accounted for 81.75% of total revenue, with a year-on-year growth of 9.40%[108]. - The internet healthcare business revenue grew by 28.38%, accounting for 18.21% of total revenue[108]. - The revenue from software products was CNY 265.83 billion, representing a year-on-year increase of 9.9%[89]. - The revenue from information technology services was CNY 701.28 billion, with a year-on-year growth of 11.7%[89]. - The company achieved operating revenue of 3,092.86 million yuan, a year-on-year increase of 12.46%[108]. - The revenue from hardware sales was approximately ¥459.21 million, with a gross margin of 11.17%[120]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a year-over-year growth of 15%[177]. Expenses and Costs - Sales expenses increased by 28.10% year-on-year, totaling ¥495,871,530.24 in 2022[2]. - R&D expenses rose by 22.73% year-on-year, amounting to ¥313,773,819.41 in 2022[2]. - The company's main business costs for 2022 amounted to 1,234,582,227.79 yuan, representing 70.89% of total operating costs, compared to 1,079,886,962.74 yuan and 73.19% in 2021, reflecting a year-on-year increase of 14.33%[48]. - Software development labor costs were 306,785,778.95 yuan, accounting for 17.62% of operating costs, up from 15.15% in 2021, marking a 37.26% increase[48]. - Hardware material costs reached 407,902,261.69 yuan, which is 23.42% of operating costs, compared to 26.02% in the previous year, with a year-on-year increase of 6.24%[48]. - Technical service labor costs were 153,438,165.94 yuan, making up 8.81% of operating costs, slightly down from 9.13% in 2021, with a year-on-year increase of 13.88%[48]. - The gross margin for the healthcare information technology sector was reported at 51.17%, a decrease of 2.11% compared to the previous year[120]. - The gross margin improved to 45%, up from 42% in the previous year, indicating better cost management[177]. Research and Development - The number of R&D personnel increased by 9.90% to 2,487 in 2022[7]. - R&D investment reached ¥625,518,769.72 in 2022, accounting for 20.22% of operating revenue[7]. - The proportion of capitalized R&D expenses to total R&D investment is 49.84% in 2022[7]. - The company is currently working on six major R&D projects aimed at enhancing product competitiveness[7]. - The company reported a total R&D capitalization amount of ¥278,299,228.09 for the development of next-generation smart medical products and cloud services, which are currently in progress[10]. - The company invested ¥625 million in R&D, accounting for 20.22% of total revenue, and obtained 47 new patents during the reporting period[114]. Cash Flow and Investments - Operating cash inflows for 2022 reached ¥3,456,104,778.63, representing a year-on-year increase of 15.51%[14]. - The net cash flow from operating activities decreased by 72.71% to ¥100,441,940.18, primarily due to increased cash payments to employees[14]. - The investment activities generated a net cash outflow of ¥349,790,906.68, reflecting a slight increase in outflows compared to the previous year[14]. - The company incurred an investment loss of ¥65,675,691.37, accounting for -170.41% of total profit, indicating significant challenges in investment performance[15]. - The total investment amount for the reporting period was ¥160,630,100, a decrease of 65.74% compared to ¥468,916,000 in the same period last year[29]. Profitability - In 2022, the company achieved a net profit attributable to shareholders of 108.44 million yuan, a decrease of 71.33% year-on-year[48]. - The net profit attributable to shareholders for 2022 was CNY 108,436,489.10, a decrease of 71.33% compared to CNY 378,174,115.45 in 2021[76]. - The basic earnings per share for 2022 was CNY 0.0507, a decline of 71.27% from CNY 0.1765 in 2021[76]. - The net profit attributable to shareholders of the listed company was approximately CNY 31.76 million, a decrease of 31.6% compared to the previous period[79]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately CNY 30.57 million, down 20.4% year-on-year[79]. Market and Industry Trends - The software and information technology service industry in China saw a revenue growth of 11.2% year-on-year, reaching CNY 1,081.26 billion in 2022[89]. - As of 2022, there are over 1,700 internet hospitals in China, with online medical user numbers exceeding 300 million, reflecting a significant increase in demand for online consultations and services[97]. - The "14th Five-Year" plan emphasizes the promotion of hospital information system cloud deployment, which is expected to enhance operational efficiency and data sharing capabilities[97]. - The integration of artificial intelligence in medical applications is being accelerated, with seven key scenarios identified for exploration, including intelligent diagnostic support and smart hospital management[93]. - The demand for data-driven systems and platforms in hospitals is increasing, as there is a need to unlock the value of accumulated data for clinical, research, and management purposes[97]. Strategic Initiatives - The company plans to focus on new product development and market expansion strategies in the upcoming year[68]. - The company is focusing on expanding its cloud services for healthcare institutions, including medical cloud and community cloud offerings[10]. - The company continues to invest in the WiNEX series products and the "Internet + Healthcare" innovation and market expansion, driven by technological innovation[48]. - The company is considering strategic acquisitions to enhance its product offerings and market presence, with a target of 500 million RMB in potential acquisitions[177]. - The company plans to enhance its digital marketing strategy, aiming for a 30% increase in online sales[177].

Order and Market Overview - In the first half of 2023, the order amount saw a slight increase compared to last year, with 21 projects exceeding 10 million [3]. - New customer acquisition in the first half of 2023 included 61 new clients contributing a contract amount of 332 million CNY, compared to 60 clients and 292 million CNY in the same period of 2022 [4]. Strategic Developments - The WiNEX design concept aligns with the future development direction of hospital information systems and has innovated in advanced technology fields [6]. - The company has made significant breakthroughs in strategic areas, including the establishment of integrated platforms and data centers to enhance connectivity and improve medical services [7]. Product and Service Enhancements - The WiNEX product line has undergone iterative upgrades, integrating over 50 external systems and enhancing core system capabilities [16]. - The introduction of a unified data service aims to provide standard data services for clinical systems and operational management [8]. Healthcare Ecosystem and Community Initiatives - The company is advancing the construction of healthcare community information systems across more than 60 county-level medical communities in various provinces [9]. - A comprehensive solution for healthcare communities has been developed, covering platforms, hospitals, and grassroots institutions [9]. Interoperability and Smart Hospital Evaluation - A total of 85 hospitals have achieved interoperability ratings of four stars or above, while 30 hospitals have reached five-star ratings for electronic medical records [10]. - The company has implemented a series of tools to enhance the delivery of services, including user research platforms and data governance tools [24]. AI and Data Utilization - The WiNGPT model has been developed to enhance decision-making capabilities through structured analysis of medical records, improving risk monitoring accuracy [44]. - The integration of AI technologies aims to streamline processes such as automatic report generation and patient health assistance [38][40]. Financial and Operational Management - The company has invested in comprehensive hospital operational management solutions, covering various aspects from human resources to financial analysis [12]. - It has established a strong presence in the medical insurance sector, focusing on digital risk control solutions and compliance monitoring [13]. Future Collaborations and Research - Recent strategic partnerships have been formed to enhance digital healthcare research and the development of generative AI models for medical applications [14]. - The company is committed to building a robust ecosystem for big data and AI in healthcare, collaborating with various institutions for knowledge sharing and resource management [14].

证券代码：300253 证券简称：卫宁健康 卫宁健康科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |------------------|---------------|-------------|----------------| | | | | 编号：2023-004 | | 投资者关系活动类 | √特定对象调研 | □分析师会议 | | 别□媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（请文字说明其他活动内容） | --- | --- | |--------------|--------------------------------------------------------------------------------------------------------------------------------| | 参与单位名称 | APS（毕盛资产）、Aspex Management（思柏投资）、LMR Partners、Tokio Marine Asset Management（东京海上国际资管）、Morgan ...